Ticiana Leal, MD, discussed the case of a 73-Year-Old woman with progressive extensive-stage small cell lung cancer.

At the moment, Amgen looks like it has a sizeable lead in the DLL3 category, with other potential indications for tarlatamab, including neuroendocrine prostate cancer (in phase 1) and potentially ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 31 December 2024, approved the medicine tarlatamab ...

The U.K.'s Medicines and Healthcare products Regulatory Agency has approved Amgen's (NASDAQ:AMGN) tarlatamab, also known as ...

Tarlatamab has been approved under the Imdelltra ... and albumin and is in a phase 1/2 trial in neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).

Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...

Amgen's Imdylltra gets MHRA nod for ES-SCLC after two prior therapies, offering new hope for aggressive cancer with limited ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved drugmaker Amgen’s (AMGN) tarlatamab (Imdyllytra ... cancer that affects about 1 in 7 lung cancer patients and ...